In studies conducted in the 4T1 model of breast carcinoma, Li et al. noted that anti-CCL2 therapy with blocking antibody led to a significant reduction in tumor volume and lung metastasis compared to the control group [60]. The gene discussed is CCL2; the disease is neoplasm.